Cardiology Research and Practice / 2016 / Article / Tab 1

Clinical Study

Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure

Table 1

Clinical characteristics.

Rosuvastatin
Placebo
value

Clinical profile
 Age [years]67 (57–72)60 (55–73)0.65
 Male gender []7 (78%)5 (56%)0.62
Characterization of CHF
 Ischemic heart disease []3 (33%)4 (44%)1.00
 LV ejection fraction [%]34 (24–36)30 (30–37)0.37
 LV end diastolic diameter [mm]64 (58–71)59 (58–65)0.19
 VO2max [mL/min/kg]13.7 (11.5–17.0)16.7 (13.8–19.1)0.18
 NYHA class II/III []4/5 (44/56%)6/3 (67/33%)0.64
Cardiac medication
 Beta blocker []9 (100%)9 (100%)n.a.
 ACE inhibitor or AT II blocker []9 (100%)9 (100%)n.a.
 Aldosterone antagonist []7 (78%)6 (67%)1.00
 Other diuretics []8 (89%)8 (89%)1.00
 Digitalis []1 (11%)3 (33%)0.24

n.a.: not applicable, median (IQR).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.